Dr Jonathan Silverberg Describes AD Diagnosis, Treatment in Children vs Adults

EP: 1.Ruxolitinib Cream Improves AD Across Body Regions, Shows Efficacy, Safety in Black Patients

EP: 2.Upcoming Generics Provide New Considerations and Opportunities for Savings

EP: 3.Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

EP: 4.Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting

EP: 5.Dermatologists’ Focus to Delve Below the Skin at Annual Conference

EP: 6.Experts Herald “Year of the JAK Inhibitor” in Dermatology

EP: 7.Dr Monica Li Highlights Advances in Microneedling

EP: 8.Dr Eva Parker: Climate Change Has Been Impacting Skin Diseases for Years

EP: 9.Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care

EP: 10.Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo

EP: 11.Late-Breaking Abstracts Demonstrate Value of Persistence With Ruxolitinib Cream for Vitiligo

EP: 12.Examining Dermatological Care for Transgender Patients

EP: 13.How Our Understanding of Inflammatory Skin Disease Has Evolved From the 4 Humors to Targeted Therapies

EP: 14.Dr Haley Naik Discusses Using Biologics and the Drug Pipeline for Hidradenitis Suppurativa

EP: 15.Drs Dellavalle and Rodriguez Discuss Disparities in Prescription Patterns for Atopic Dermatitis

EP: 16.Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability

EP: 17.Investigators Highlight Disparities Evident in Skin Disease Care, Data Collection

EP: 18.Studies Presented at AAD Examine Safety and Satisfaction of Tildrakizumab for Psoriasis

EP: 19.Patients With AD Have More Options With Biologics, JAK Inhibitors, Says Dr Emma Guttman-Yassky

EP: 20.Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says

EP: 21.Teledermatology Can Increase Access for Patients With High-Risk Melanoma: Erik Jaklitsch

EP: 22.Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early

EP: 23.Panel Discusses Treating Acne, Psoriasis in Dermatology Patients

EP: 24.New and Upcoming Treatment for Vitiligo, Atopic Dermatitis

EP: 25.Long-Term Safety of Dupilumab in Adults With Moderate to Severe Atopic Dermatitis

EP: 26.Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment

EP: 27.ICYMI: Highlights From RAD 2023

EP: 28.AAD 2024 to Feature Topics Including JAK Inhibitors, Biologics

EP: 29.Dr Amy Paller Previews the 2024 AAD Annual Conference

EP: 30.Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments

EP: 31.Dr Raj Chovatiya Outlines Who Is a Good Candidate for Oral JAK Inhibitors

EP: 32.Atopic Dermatitis in Adults: Challenges and Treatment Strategies

EP: 33.Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful

EP: 34.Dr Monica Li Discusses Tailoring Microneedling Treatments to Meet Each Patient's Need

EP: 35.Skin Tone Bias Persists in Google Searches for Vitiligo

EP: 36.Management of HS Requires Both Coordination, Communication Between Patients and Providers

EP: 37.Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks

EP: 38.Biologic, Topical Therapies Both Effective in Treating AD in Skin of Color

EP: 39.Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

EP: 40.Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

EP: 41.Dr Martin Dahl Discusses the Pathophysiology of AD and Benefits of ANB032

EP: 42.New Study Links Social Factors to Hidradenitis Suppurativa Severity

EP: 43.Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis

EP: 44.Dr Shawn Kwatra Shares Efficacy, Safety Data of Nemolizumab in Patients With PN

EP: 45.Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis

EP: 46.Patients With Vitiligo Suffer Heightened Stigma, Mental Health Risks

EP: 47.Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study

EP: 48.Autoimmune Comorbidities Prevalent in Patients With Vitiligo

EP: 49.Skin Cancer Incidence Highest Among Rural, SOC Individuals

EP: 50.Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD

EP: 51.Gaps in Skincare Knowledge, Sun Protection Practice Exist Among Patients With Lupus

EP: 52.Dr Raj Chovatiya Provides Evidence Supporting Oral JAK Inhibitor Use to Treat AD

EP: 53.Undertreatment, Biologic Access Gaps Identified in Psoriasis Treatment

EP: 54.Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment

EP: 55.Dr Monica Li Lists Microneedling Considerations, Precautions

Now Viewing

EP: 56.Dr Jonathan Silverberg Describes AD Diagnosis, Treatment in Children vs Adults

EP: 57.Dr Lawrence Eichenfield Discusses Positive Results of Roflumilast Cream 0.05% in Pediatric Patients With AD

EP: 58.Dr Robert Sidbury on Implementing Value-Based Care Initiatives in a Pediatric Dermatology Practice

EP: 59.Dr Monica Li Explains Efficacy, Safety Differences Between Different Microneedling Techniques

EP: 60.Dr Lawrence Eichenfield Hopeful for New Pediatric AD Treatment Option

EP: 61.Dr Martina Porter Shares Findings on Ruxolitinib Cream in Patients With HS

This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.

Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology and director of clinical research and patch testing at George Washington University School of Medicine and Health Sciences, discusses how dermatologists diagnose and treat atopic dermatitis (AD) in children vs adults.

He also described how the ARCADIA-1 and ARCADIA-2 study results show nemolizumab's potential as a maintenance therapy for AD.

Transcript

How do dermatologists diagnose AD in children? How does AD present differently in adults?

Atopic dermatitis is really a clinical diagnosis. We look at a constellation of clinical history, physical exam, family history, etc, looking at things like presence of itch, age of onset, the distribution of lesions, etc. The criteria for diagnosing atopic dermatitis are generally the same between children and adults, but the the presentation can vary substantially across age groups.

So, in children, it's usually a fairly straightforward diagnosis, although, certainly, there are mimics that we have to think about. But in adults, it can be much more challenging because the differential diagnosis is broader, we see a lot less flexural involvement, we tend to see more of these sort of morphologic variants that are a little less common in childhood appear more so in adults. So there's a lot of different things that we need to take into account as we're trying to make this diagnosis correctly in adults.

What are some key differences when treating children with AD compared with treating adults with AD?

So, treatment wise, some of it is just practical. There's certain therapies that are approved down to young children. For example, dupilumab is approved down to age 6 months for moderate to severe disease. Many of the other therapies are not there yet. They're running their studies still for younger children, but, technically, we don't have them approved.

Some of it may actually be theoretical differences that turn out to be practical in the sense that it may be that certain targeted therapies will work better in some age groups than others. It may be that some of the targeted therapies may work better in adults than they even do in children.

For a disease that is so common in childhood, so much of the development really hinges upon the adult population, but then we're often left with that question, will we expect the same response for children as we see for adults?

What insights do the ARCADIA-1 and ARCADIA-2 study results provide regarding the potential for nemolizumab as a maintenance therapy for moderate to severe AD?

It's important to recognize that atopic dermatitis is a chronic disease and, for many, lifelong, which means it needs to be treated chronically. The field has worked very hard over the past 2 decades to acknowledge that and develop good long-term treatment approaches.

Like many other targeted therapies, nemolizumab is not supposed to be used for just a quick fix for a few weeks. If we're going to be using it, for many patients, it's going to be necessary to use it for months and perhaps years on end. So, it's very important that we understand what are the long-term efficacy profiles for different drugs that we use, and, particularly, in this case, for nemolizumab.

What we're seeing here is, in that longer-term use scenario, we're seeing nice durability of response, no loss of efficacy over time. We're also seeing an opportunity that there may be a dose-flexibility opportunity where we might, for some patients, not have to even use it every month, but may be able to give it every other month, which is fewer shots and certainly something that is going to be more meaningful for patients.

For some, there might even be an opportunity to take a little drug holiday and discontinue, as we saw from the placebo arm. So, I think this provides very important information about sort of real-world use long term that is very clinically valuable.